EyeGate Raises $22.6M In Venture Funding
The money will be used to further the company’s development of EGP-437 to treat dry eye syndrome.
Blog
Enzon and Sopherion Make Breast Cancer Progress
Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.
As Seasonal Flu Ramps Up, NexBio Begins Phase II Trial for DAS181
DAS181 is formulated to prevent the influenza virus from entering cells in the respiratory tract.
NeoPharm to Investigate Treatment for Deadly Lung Disease
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
Implantable Weight-Loss Device Receives CE Mark Approval
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.
Resverlogix to Begin Phase II Atherosclerosis Trial
Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.
Researchers Identify Gene Linked to Childhood Asthma
U.S. researchers have identified a gene that is linked to childhood asthma.
Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
New Era Begins for NeoStem Following China Acquisition
NeoStem is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications.
Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).